| Hans-Günter Meyer-Thompson | Buprenorphin
Superiority and cost-effectiveness of monthly extended-release buprenorphine versus daily standard of care medication: a pragmatic, parallel-group, open-label, multicentre, randomised, controlled, phase 3 trial
Superiority and cost-effectiveness of monthly extended-release buprenorphine versus daily standard of care medication: a pragmatic, parallel-group, open-label, multicentre, randomised, controlled, phase 3 trial
John Marsden, Mike Kelleher, Eilish Gilvarry, Luke Mitcheson, Jatinder Bisla, Angela Cape, Fiona Cowden, Edward Day, Jonathan Dewhurst, Rachel Evans, Will Hardy, Andrea Hearn, Joanna Kelly, Natalie Lowry, Martin McCusker, Caroline Murphy, Robert Murray, Tracey Myton, Sophie Quarshie, Rob Vanderwaal, April Wareham, Dyfrig Hughes, Zoë Hoare,
eClinicalMedicine, Volume 66, 2023, 102311, ISSN 2589-5370, doi.org/10.1016/j.eclinm.2023.102311.
https://www.sciencedirect.com/science/article/pii/S2589537023004881